Richard Vandivier
Concepts (441)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 21 | 2025 | 1049 | 3.140 |
Why?
| | Apoptosis | 23 | 2014 | 2574 | 2.090 |
Why?
| | Phagocytosis | 15 | 2014 | 388 | 1.930 |
Why?
| | Macrophages, Alveolar | 14 | 2019 | 396 | 1.170 |
Why?
| | Tobacco Smoke Pollution | 3 | 2022 | 256 | 1.120 |
Why?
| | Tissue Plasminogen Activator | 2 | 2018 | 235 | 1.010 |
Why?
| | Pulmonary Embolism | 2 | 2018 | 239 | 0.970 |
Why?
| | Respiratory Insufficiency | 4 | 2024 | 326 | 0.870 |
Why?
| | Lung | 13 | 2025 | 4134 | 0.710 |
Why?
| | Smoking | 5 | 2018 | 1601 | 0.690 |
Why?
| | Adrenal Cortex Hormones | 2 | 2015 | 501 | 0.690 |
Why?
| | Cigarette Smoking | 2 | 2025 | 103 | 0.680 |
Why?
| | rhoA GTP-Binding Protein | 6 | 2014 | 88 | 0.640 |
Why?
| | Pulmonary Ventilation | 2 | 2018 | 84 | 0.600 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2022 | 344 | 0.570 |
Why?
| | Pneumonia | 6 | 2023 | 656 | 0.540 |
Why?
| | Delivery of Health Care, Integrated | 2 | 2011 | 289 | 0.520 |
Why?
| | Fibrinolytic Agents | 1 | 2018 | 283 | 0.480 |
Why?
| | rac1 GTP-Binding Protein | 3 | 2012 | 58 | 0.440 |
Why?
| | Pulmonary Alveoli | 4 | 2016 | 410 | 0.440 |
Why?
| | Stem Cells | 2 | 2018 | 602 | 0.440 |
Why?
| | Methylprednisolone | 1 | 2014 | 64 | 0.420 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2014 | 68 | 0.410 |
Why?
| | Critical Illness | 8 | 2020 | 837 | 0.410 |
Why?
| | Pulmonary Surfactant-Associated Protein D | 5 | 2016 | 34 | 0.400 |
Why?
| | Hospital Mortality | 6 | 2025 | 924 | 0.400 |
Why?
| | Asthma | 3 | 2022 | 1913 | 0.400 |
Why?
| | Bronchiectasis | 2 | 2006 | 112 | 0.390 |
Why?
| | Intensive Care Units | 6 | 2025 | 868 | 0.380 |
Why?
| | Hypnotics and Sedatives | 2 | 2025 | 214 | 0.380 |
Why?
| | Alcoholism | 5 | 2023 | 821 | 0.380 |
Why?
| | Case Management | 1 | 2012 | 67 | 0.380 |
Why?
| | Coronary Disease | 1 | 2015 | 371 | 0.380 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2016 | 550 | 0.370 |
Why?
| | Humans | 67 | 2025 | 141197 | 0.370 |
Why?
| | rho GTP-Binding Proteins | 2 | 2010 | 60 | 0.370 |
Why?
| | Serotonin | 1 | 2014 | 323 | 0.360 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 72 | 0.360 |
Why?
| | Noninvasive Ventilation | 2 | 2024 | 57 | 0.350 |
Why?
| | Cystic Fibrosis | 4 | 2006 | 1126 | 0.330 |
Why?
| | Pulmonary Surfactant-Associated Protein A | 3 | 2008 | 33 | 0.320 |
Why?
| | Patient Education as Topic | 2 | 2012 | 778 | 0.320 |
Why?
| | Inflammation Mediators | 4 | 2016 | 519 | 0.300 |
Why?
| | Mice | 21 | 2017 | 18055 | 0.290 |
Why?
| | Neutrophils | 7 | 2010 | 1282 | 0.290 |
Why?
| | Male | 38 | 2025 | 69789 | 0.290 |
Why?
| | Jurkat Cells | 6 | 2012 | 138 | 0.280 |
Why?
| | Interleukin-8 | 1 | 2009 | 273 | 0.280 |
Why?
| | Low Density Lipoprotein Receptor-Related Protein-1 | 3 | 2006 | 19 | 0.270 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2018 | 2064 | 0.270 |
Why?
| | Female | 36 | 2025 | 75522 | 0.270 |
Why?
| | Signal Transduction | 6 | 2014 | 5144 | 0.270 |
Why?
| | Hospitalization | 5 | 2023 | 2255 | 0.270 |
Why?
| | Cells, Cultured | 9 | 2016 | 4208 | 0.260 |
Why?
| | Benzodiazepines | 2 | 2025 | 156 | 0.260 |
Why?
| | Animals | 30 | 2017 | 37663 | 0.260 |
Why?
| | Middle Aged | 23 | 2025 | 34438 | 0.260 |
Why?
| | Acyl Coenzyme A | 1 | 2006 | 30 | 0.250 |
Why?
| | Intracellular Fluid | 1 | 2006 | 26 | 0.250 |
Why?
| | rho-Associated Kinases | 3 | 2014 | 84 | 0.250 |
Why?
| | Lovastatin | 1 | 2006 | 38 | 0.250 |
Why?
| | Inflammation | 9 | 2016 | 2889 | 0.250 |
Why?
| | Lung Diseases, Obstructive | 1 | 2006 | 47 | 0.240 |
Why?
| | Collectins | 1 | 2006 | 11 | 0.240 |
Why?
| | Opsonin Proteins | 1 | 2006 | 24 | 0.240 |
Why?
| | Quality of Life | 3 | 2022 | 2999 | 0.240 |
Why?
| | Self Care | 1 | 2009 | 395 | 0.240 |
Why?
| | Chemotaxis, Leukocyte | 1 | 2006 | 145 | 0.240 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2009 | 348 | 0.240 |
Why?
| | Ethanol | 1 | 2010 | 629 | 0.240 |
Why?
| | Retrospective Studies | 13 | 2025 | 16273 | 0.230 |
Why?
| | Leukocyte Elastase | 2 | 2002 | 75 | 0.230 |
Why?
| | Neuromuscular Blockade | 1 | 2025 | 45 | 0.230 |
Why?
| | Mice, Knockout | 8 | 2014 | 3068 | 0.220 |
Why?
| | Propofol | 1 | 2025 | 89 | 0.220 |
Why?
| | Mice, Inbred C57BL | 11 | 2014 | 5887 | 0.210 |
Why?
| | Oligopeptides | 1 | 2006 | 266 | 0.210 |
Why?
| | Influenza A virus | 1 | 2025 | 111 | 0.210 |
Why?
| | Shock, Septic | 2 | 2022 | 210 | 0.210 |
Why?
| | Cohort Studies | 6 | 2022 | 5799 | 0.210 |
Why?
| | Complement C1q | 2 | 2006 | 38 | 0.210 |
Why?
| | Ibuprofen | 4 | 2001 | 83 | 0.210 |
Why?
| | Disease Progression | 4 | 2020 | 2793 | 0.200 |
Why?
| | Patient Admission | 1 | 2025 | 203 | 0.200 |
Why?
| | Erythropoietin | 1 | 2004 | 98 | 0.200 |
Why?
| | Lipopolysaccharides | 5 | 2016 | 889 | 0.200 |
Why?
| | Respiratory System | 2 | 2018 | 157 | 0.200 |
Why?
| | Aged | 16 | 2025 | 24576 | 0.200 |
Why?
| | Intracellular Signaling Peptides and Proteins | 2 | 2025 | 464 | 0.190 |
Why?
| | Calreticulin | 1 | 2002 | 28 | 0.190 |
Why?
| | Extracellular Matrix | 1 | 2006 | 555 | 0.180 |
Why?
| | Adult | 21 | 2025 | 39181 | 0.180 |
Why?
| | Patient Discharge | 2 | 2018 | 932 | 0.170 |
Why?
| | Smoke-Free Policy | 1 | 2021 | 13 | 0.170 |
Why?
| | Treatment Outcome | 5 | 2022 | 11120 | 0.170 |
Why?
| | Macrophages | 5 | 2010 | 1560 | 0.170 |
Why?
| | Transforming Growth Factor beta | 4 | 2013 | 497 | 0.170 |
Why?
| | Smokers | 2 | 2019 | 144 | 0.170 |
Why?
| | Tumor Necrosis Factor-alpha | 6 | 2009 | 1250 | 0.160 |
Why?
| | Mice, Inbred ICR | 3 | 2013 | 119 | 0.160 |
Why?
| | Endotoxins | 5 | 2013 | 220 | 0.160 |
Why?
| | Autoimmune Diseases | 2 | 2014 | 464 | 0.160 |
Why?
| | Receptors, Cell Surface | 1 | 2002 | 397 | 0.160 |
Why?
| | Analgesics, Opioid | 2 | 2025 | 1116 | 0.160 |
Why?
| | Nitroprusside | 1 | 1999 | 72 | 0.150 |
Why?
| | Granulomatous Disease, Chronic | 2 | 2010 | 59 | 0.150 |
Why?
| | Speech Therapy | 1 | 2019 | 21 | 0.150 |
Why?
| | Hexosaminidases | 1 | 2019 | 18 | 0.150 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2018 | 37 | 0.150 |
Why?
| | Macrolides | 1 | 2019 | 67 | 0.150 |
Why?
| | Pharmacoepidemiology | 2 | 2019 | 21 | 0.150 |
Why?
| | Influenza, Human | 1 | 2025 | 626 | 0.140 |
Why?
| | Vecuronium Bromide | 1 | 2018 | 7 | 0.140 |
Why?
| | Atracurium | 1 | 2018 | 14 | 0.140 |
Why?
| | Heart Failure, Diastolic | 1 | 2018 | 23 | 0.140 |
Why?
| | Heart Failure, Systolic | 1 | 2018 | 25 | 0.140 |
Why?
| | Neuromuscular Blocking Agents | 1 | 2018 | 25 | 0.140 |
Why?
| | Coronary Circulation | 1 | 2018 | 136 | 0.140 |
Why?
| | Cardiologists | 1 | 2018 | 45 | 0.140 |
Why?
| | Bronchoalveolar Lavage Fluid | 5 | 2016 | 650 | 0.140 |
Why?
| | Intubation, Intratracheal | 1 | 2020 | 286 | 0.140 |
Why?
| | Time | 1 | 2018 | 87 | 0.140 |
Why?
| | Counseling | 1 | 2021 | 398 | 0.130 |
Why?
| | Occupational Therapy | 1 | 2019 | 99 | 0.130 |
Why?
| | Polyneuropathies | 1 | 2017 | 57 | 0.130 |
Why?
| | Up-Regulation | 2 | 2019 | 859 | 0.130 |
Why?
| | Factor Xa Inhibitors | 1 | 2018 | 175 | 0.130 |
Why?
| | Aged, 80 and over | 7 | 2022 | 7856 | 0.130 |
Why?
| | Epithelium | 1 | 2018 | 316 | 0.130 |
Why?
| | Hypertension, Pulmonary | 4 | 2016 | 1935 | 0.130 |
Why?
| | Disease Models, Animal | 5 | 2017 | 4405 | 0.130 |
Why?
| | Disease-Free Survival | 1 | 2018 | 715 | 0.130 |
Why?
| | Nitric Oxide | 3 | 2006 | 900 | 0.130 |
Why?
| | Ventricular Function, Left | 2 | 2018 | 513 | 0.130 |
Why?
| | Anti-Bacterial Agents | 2 | 2019 | 1865 | 0.130 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2018 | 213 | 0.120 |
Why?
| | Practice Patterns, Physicians' | 1 | 2025 | 1336 | 0.120 |
Why?
| | Propensity Score | 2 | 2017 | 328 | 0.120 |
Why?
| | Substance-Related Disorders | 1 | 2025 | 1100 | 0.120 |
Why?
| | Critical Care | 2 | 2020 | 649 | 0.120 |
Why?
| | Receptors, IgG | 2 | 2009 | 77 | 0.120 |
Why?
| | Environmental Exposure | 1 | 2021 | 582 | 0.120 |
Why?
| | DNA, Bacterial | 1 | 2017 | 339 | 0.120 |
Why?
| | Physical Therapy Modalities | 1 | 2019 | 316 | 0.120 |
Why?
| | Antibodies, Monoclonal | 2 | 2014 | 1448 | 0.120 |
Why?
| | Respiratory Tract Diseases | 1 | 2017 | 181 | 0.120 |
Why?
| | Length of Stay | 3 | 2019 | 1254 | 0.120 |
Why?
| | Respiratory Mucosa | 2 | 2009 | 330 | 0.110 |
Why?
| | Emphysema | 3 | 2012 | 116 | 0.110 |
Why?
| | Opioid-Related Disorders | 1 | 2023 | 562 | 0.110 |
Why?
| | CD36 Antigens | 2 | 2006 | 36 | 0.110 |
Why?
| | Biopsy | 1 | 2018 | 1081 | 0.110 |
Why?
| | Gene Expression Regulation | 4 | 2014 | 2599 | 0.110 |
Why?
| | Venous Thromboembolism | 1 | 2018 | 337 | 0.110 |
Why?
| | Hyaluronan Receptors | 2 | 2006 | 103 | 0.100 |
Why?
| | Anticoagulants | 1 | 2018 | 675 | 0.100 |
Why?
| | Schistosomiasis mansoni | 1 | 2013 | 27 | 0.100 |
Why?
| | Schistosoma mansoni | 1 | 2013 | 43 | 0.100 |
Why?
| | Gastrointestinal Agents | 1 | 2014 | 67 | 0.100 |
Why?
| | Epithelial Cells | 3 | 2025 | 1110 | 0.100 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2014 | 346 | 0.100 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2016 | 243 | 0.100 |
Why?
| | Leukocytes, Mononuclear | 1 | 2016 | 573 | 0.100 |
Why?
| | Echocardiography | 1 | 2016 | 643 | 0.100 |
Why?
| | Biological Transport | 1 | 2014 | 407 | 0.100 |
Why?
| | Thymus Gland | 1 | 2014 | 319 | 0.100 |
Why?
| | Respiration, Artificial | 3 | 2025 | 683 | 0.100 |
Why?
| | Interleukin-6 | 3 | 2013 | 792 | 0.090 |
Why?
| | Patient Acceptance of Health Care | 1 | 2019 | 878 | 0.090 |
Why?
| | Mice, Transgenic | 3 | 2013 | 2181 | 0.090 |
Why?
| | Cell Line | 4 | 2012 | 2885 | 0.090 |
Why?
| | Acute Disease | 1 | 2015 | 1008 | 0.090 |
Why?
| | Doxycycline | 1 | 2012 | 61 | 0.090 |
Why?
| | Phosphatidylserines | 2 | 2008 | 88 | 0.090 |
Why?
| | Acetylcysteine | 2 | 2016 | 142 | 0.090 |
Why?
| | United States | 7 | 2025 | 15220 | 0.090 |
Why?
| | Colitis | 1 | 2014 | 266 | 0.090 |
Why?
| | Pyrroles | 1 | 2012 | 210 | 0.080 |
Why?
| | Bronchoalveolar Lavage | 3 | 2017 | 92 | 0.080 |
Why?
| | Erythrocytes | 2 | 2009 | 707 | 0.080 |
Why?
| | Glucocorticoids | 1 | 2015 | 533 | 0.080 |
Why?
| | Anti-Inflammatory Agents | 1 | 2014 | 482 | 0.080 |
Why?
| | Multivariate Analysis | 1 | 2014 | 1490 | 0.080 |
Why?
| | Membrane Glycoproteins | 3 | 2010 | 501 | 0.080 |
Why?
| | Adolescent | 5 | 2022 | 22007 | 0.080 |
Why?
| | Rural Health Services | 1 | 2011 | 141 | 0.080 |
Why?
| | In Vitro Techniques | 2 | 2002 | 1093 | 0.080 |
Why?
| | Membrane Proteins | 3 | 2006 | 1155 | 0.080 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2892 | 0.080 |
Why?
| | Ceramides | 1 | 2010 | 118 | 0.080 |
Why?
| | Sepsis | 3 | 2020 | 616 | 0.080 |
Why?
| | Peritonitis | 1 | 2010 | 87 | 0.080 |
Why?
| | Health Care Surveys | 1 | 2011 | 565 | 0.080 |
Why?
| | Amides | 1 | 2010 | 100 | 0.080 |
Why?
| | Acute Lung Injury | 1 | 2013 | 304 | 0.080 |
Why?
| | Stress Fibers | 1 | 2009 | 19 | 0.080 |
Why?
| | Amiloride | 1 | 2009 | 27 | 0.080 |
Why?
| | Thiazolidinediones | 1 | 2010 | 138 | 0.080 |
Why?
| | Endotoxemia | 2 | 2001 | 87 | 0.080 |
Why?
| | Phosphorylation | 1 | 2014 | 1768 | 0.080 |
Why?
| | Microbiota | 1 | 2017 | 767 | 0.080 |
Why?
| | Alcohol-Related Disorders | 1 | 2010 | 125 | 0.080 |
Why?
| | PPAR gamma | 1 | 2010 | 181 | 0.080 |
Why?
| | Oxygen Consumption | 1 | 2011 | 715 | 0.070 |
Why?
| | Indoles | 1 | 2012 | 429 | 0.070 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 771 | 0.070 |
Why?
| | Antigens, Differentiation | 1 | 2008 | 82 | 0.070 |
Why?
| | Statistics, Nonparametric | 1 | 2009 | 434 | 0.070 |
Why?
| | Interleukin-4 | 1 | 2008 | 215 | 0.070 |
Why?
| | Risk Factors | 4 | 2018 | 10438 | 0.070 |
Why?
| | Telephone | 1 | 2009 | 182 | 0.070 |
Why?
| | Gene Expression | 2 | 2010 | 1491 | 0.070 |
Why?
| | Actins | 1 | 2009 | 423 | 0.060 |
Why?
| | Receptors, Immunologic | 1 | 2008 | 215 | 0.060 |
Why?
| | Blotting, Western | 1 | 2009 | 1234 | 0.060 |
Why?
| | Free Radical Scavengers | 1 | 2006 | 87 | 0.060 |
Why?
| | Hydroxymethylglutaryl CoA Reductases | 1 | 2006 | 14 | 0.060 |
Why?
| | Heart Rate | 3 | 2005 | 821 | 0.060 |
Why?
| | Protein Prenylation | 1 | 2006 | 34 | 0.060 |
Why?
| | Cross-Sectional Studies | 1 | 2018 | 5636 | 0.060 |
Why?
| | Pyridines | 1 | 2010 | 510 | 0.060 |
Why?
| | Models, Biological | 1 | 2014 | 1828 | 0.060 |
Why?
| | Mannose-Binding Lectin | 1 | 2006 | 21 | 0.060 |
Why?
| | Down-Regulation | 2 | 2025 | 641 | 0.060 |
Why?
| | Lysophospholipids | 1 | 2006 | 80 | 0.060 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2006 | 120 | 0.060 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2006 | 175 | 0.060 |
Why?
| | Protein Biosynthesis | 1 | 2008 | 444 | 0.060 |
Why?
| | Parenteral Nutrition | 1 | 2006 | 105 | 0.060 |
Why?
| | Transcription, Genetic | 2 | 2010 | 1487 | 0.060 |
Why?
| | Receptors, Complement | 1 | 2006 | 122 | 0.060 |
Why?
| | omega-N-Methylarginine | 1 | 2005 | 31 | 0.060 |
Why?
| | Arginine | 1 | 2006 | 261 | 0.060 |
Why?
| | Health Care Costs | 1 | 2009 | 424 | 0.060 |
Why?
| | Bronchi | 1 | 2006 | 270 | 0.060 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 1 | 2025 | 51 | 0.060 |
Why?
| | Antigens, CD | 2 | 2006 | 539 | 0.060 |
Why?
| | Regeneration | 1 | 2006 | 198 | 0.060 |
Why?
| | Patient Satisfaction | 1 | 2009 | 695 | 0.050 |
Why?
| | Single-Blind Method | 3 | 2001 | 288 | 0.050 |
Why?
| | MAP Kinase Signaling System | 1 | 2006 | 325 | 0.050 |
Why?
| | Longitudinal Studies | 1 | 2011 | 2902 | 0.050 |
Why?
| | HIV Infections | 1 | 2019 | 3017 | 0.050 |
Why?
| | Blood Pressure | 3 | 2016 | 1748 | 0.050 |
Why?
| | Collagen | 1 | 2006 | 459 | 0.050 |
Why?
| | Nitrates | 2 | 2005 | 97 | 0.050 |
Why?
| | Neoplasms | 1 | 2018 | 2741 | 0.050 |
Why?
| | Monocytes | 1 | 2006 | 579 | 0.050 |
Why?
| | Analgesia | 1 | 2024 | 102 | 0.050 |
Why?
| | Fibroblasts | 1 | 2008 | 1020 | 0.050 |
Why?
| | Lung Diseases | 2 | 2009 | 794 | 0.050 |
Why?
| | Databases, Factual | 2 | 2019 | 1444 | 0.050 |
Why?
| | Patient Readmission | 2 | 2019 | 706 | 0.050 |
Why?
| | Complement Activation | 1 | 2006 | 414 | 0.050 |
Why?
| | Antineoplastic Agents | 1 | 2014 | 2166 | 0.050 |
Why?
| | Pulmonary Surfactant-Associated Proteins | 1 | 2002 | 10 | 0.050 |
Why?
| | Cathepsin G | 1 | 2002 | 6 | 0.050 |
Why?
| | Proteolipids | 1 | 2002 | 29 | 0.050 |
Why?
| | Cathepsins | 1 | 2002 | 23 | 0.050 |
Why?
| | Fever | 3 | 2001 | 308 | 0.050 |
Why?
| | Oxidative Stress | 1 | 2009 | 1331 | 0.050 |
Why?
| | Macromolecular Substances | 1 | 2002 | 226 | 0.050 |
Why?
| | Immunotherapy | 1 | 2006 | 641 | 0.050 |
Why?
| | Vasopressins | 1 | 2022 | 60 | 0.050 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 453 | 0.050 |
Why?
| | Heart Diseases | 1 | 2005 | 335 | 0.040 |
Why?
| | Jumonji Domain-Containing Histone Demethylases | 1 | 2002 | 63 | 0.040 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2001 | 78 | 0.040 |
Why?
| | Vasoconstrictor Agents | 1 | 2022 | 134 | 0.040 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 209 | 0.040 |
Why?
| | Colorado | 1 | 2011 | 4610 | 0.040 |
Why?
| | Norepinephrine | 1 | 2022 | 193 | 0.040 |
Why?
| | Serine Endopeptidases | 1 | 2002 | 119 | 0.040 |
Why?
| | Pulmonary Surfactants | 1 | 2002 | 106 | 0.040 |
Why?
| | Critical Care Outcomes | 1 | 2020 | 11 | 0.040 |
Why?
| | Carbon Dioxide | 2 | 2001 | 243 | 0.040 |
Why?
| | Status Asthmaticus | 1 | 2020 | 13 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2009 | 3470 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2004 | 1357 | 0.040 |
Why?
| | Cell Differentiation | 1 | 2008 | 2003 | 0.040 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2001 | 348 | 0.040 |
Why?
| | Cell Communication | 1 | 2002 | 318 | 0.040 |
Why?
| | Vascular Resistance | 2 | 2016 | 364 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2025 | 660 | 0.040 |
Why?
| | Sputum | 1 | 2002 | 309 | 0.040 |
Why?
| | Young Adult | 4 | 2019 | 13673 | 0.040 |
Why?
| | Chronic Disease | 1 | 2006 | 1816 | 0.040 |
Why?
| | Glycoproteins | 1 | 2002 | 356 | 0.040 |
Why?
| | Autoimmunity | 1 | 2006 | 908 | 0.040 |
Why?
| | NADPH Oxidase 2 | 2 | 2010 | 41 | 0.040 |
Why?
| | Cross-Over Studies | 2 | 1999 | 578 | 0.040 |
Why?
| | Dyspnea | 1 | 2001 | 257 | 0.040 |
Why?
| | Cyclic GMP | 1 | 1999 | 91 | 0.040 |
Why?
| | Macrophage Inflammatory Proteins | 1 | 1999 | 11 | 0.040 |
Why?
| | NADPH Oxidases | 2 | 2010 | 140 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2017 | 3588 | 0.040 |
Why?
| | Mice, Inbred BALB C | 2 | 2013 | 1274 | 0.040 |
Why?
| | Endothelium, Vascular | 2 | 2003 | 951 | 0.040 |
Why?
| | Prevalence | 1 | 2025 | 2772 | 0.040 |
Why?
| | Infusions, Intravenous | 1 | 1999 | 417 | 0.040 |
Why?
| | Hospitals, Rural | 1 | 2018 | 44 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2004 | 1556 | 0.030 |
Why?
| | Hospital Charges | 1 | 2017 | 45 | 0.030 |
Why?
| | Hospitals, Urban | 1 | 2018 | 137 | 0.030 |
Why?
| | Comparative Effectiveness Research | 1 | 2018 | 164 | 0.030 |
Why?
| | Cellular Reprogramming | 1 | 2018 | 99 | 0.030 |
Why?
| | Time Factors | 2 | 2018 | 6956 | 0.030 |
Why?
| | Muscular Diseases | 1 | 2017 | 112 | 0.030 |
Why?
| | Bayes Theorem | 1 | 2019 | 417 | 0.030 |
Why?
| | Thrombocytopenia | 1 | 2018 | 208 | 0.030 |
Why?
| | Protein Binding | 1 | 2002 | 2239 | 0.030 |
Why?
| | Teichoic Acids | 1 | 2016 | 14 | 0.030 |
Why?
| | Cytokines | 3 | 2013 | 2098 | 0.030 |
Why?
| | Biomarkers | 2 | 2019 | 4175 | 0.030 |
Why?
| | Surveys and Questionnaires | 1 | 2009 | 5929 | 0.030 |
Why?
| | Receptors, Interleukin-1 | 1 | 1996 | 215 | 0.030 |
Why?
| | Acute Kidney Injury | 2 | 2014 | 819 | 0.030 |
Why?
| | Systole | 1 | 2016 | 174 | 0.030 |
Why?
| | Comorbidity | 1 | 2020 | 1662 | 0.030 |
Why?
| | Capillary Permeability | 1 | 2016 | 149 | 0.030 |
Why?
| | Lung Diseases, Interstitial | 1 | 2002 | 655 | 0.030 |
Why?
| | Risk | 1 | 2018 | 904 | 0.030 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 2 | 2009 | 44 | 0.030 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2017 | 557 | 0.030 |
Why?
| | Toll-Like Receptor 2 | 1 | 2016 | 120 | 0.030 |
Why?
| | Cell Membrane | 2 | 2010 | 724 | 0.030 |
Why?
| | Transcription Factors | 1 | 2003 | 1703 | 0.030 |
Why?
| | Amino Acid Oxidoreductases | 1 | 1994 | 18 | 0.030 |
Why?
| | Dogs | 2 | 2006 | 427 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 824 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 2016 | 596 | 0.030 |
Why?
| | Immunologic Factors | 1 | 1996 | 248 | 0.030 |
Why?
| | Ipilimumab | 1 | 2014 | 35 | 0.030 |
Why?
| | ROC Curve | 1 | 2016 | 586 | 0.030 |
Why?
| | Recombinant Fusion Proteins | 1 | 1996 | 672 | 0.030 |
Why?
| | Flow Cytometry | 2 | 2009 | 1197 | 0.030 |
Why?
| | Infliximab | 1 | 2014 | 111 | 0.030 |
Why?
| | Toll-Like Receptor 4 | 1 | 2016 | 276 | 0.030 |
Why?
| | Hemorrhage | 1 | 2018 | 760 | 0.030 |
Why?
| | Mice, 129 Strain | 1 | 2013 | 86 | 0.030 |
Why?
| | Blood Urea Nitrogen | 1 | 2013 | 54 | 0.030 |
Why?
| | Diarrhea | 1 | 2014 | 183 | 0.020 |
Why?
| | Hypotension | 1 | 2014 | 122 | 0.020 |
Why?
| | Phylogeny | 1 | 2017 | 1018 | 0.020 |
Why?
| | Endothelial Cells | 2 | 2010 | 816 | 0.020 |
Why?
| | Logistic Models | 1 | 2017 | 2086 | 0.020 |
Why?
| | Cardiac Catheterization | 1 | 2016 | 537 | 0.020 |
Why?
| | Transfection | 2 | 2006 | 943 | 0.020 |
Why?
| | Vasoconstriction | 1 | 2013 | 219 | 0.020 |
Why?
| | Antioxidants | 1 | 2016 | 595 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 2 | 2010 | 2520 | 0.020 |
Why?
| | Healthcare Disparities | 1 | 2018 | 666 | 0.020 |
Why?
| | Trachea | 1 | 2013 | 255 | 0.020 |
Why?
| | Pulmonary Circulation | 1 | 2013 | 438 | 0.020 |
Why?
| | Creatinine | 1 | 2013 | 489 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 1999 | 3348 | 0.020 |
Why?
| | Ceramidases | 1 | 2010 | 4 | 0.020 |
Why?
| | Zymosan | 1 | 2010 | 66 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2013 | 1320 | 0.020 |
Why?
| | Nitric Oxide Synthase | 2 | 2005 | 242 | 0.020 |
Why?
| | Lung Compliance | 1 | 2009 | 50 | 0.020 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2009 | 84 | 0.020 |
Why?
| | RNA, Messenger | 2 | 2010 | 2828 | 0.020 |
Why?
| | Gene Deletion | 1 | 2010 | 388 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 987 | 0.020 |
Why?
| | Rats | 2 | 2010 | 5629 | 0.020 |
Why?
| | Capillaries | 1 | 2009 | 125 | 0.020 |
Why?
| | 3T3 Cells | 1 | 2008 | 164 | 0.020 |
Why?
| | Binding, Competitive | 1 | 2008 | 196 | 0.020 |
Why?
| | Leukocytes | 1 | 2009 | 309 | 0.020 |
Why?
| | Pulmonary Emphysema | 1 | 2010 | 312 | 0.020 |
Why?
| | Interleukin-10 | 1 | 2009 | 310 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 855 | 0.020 |
Why?
| | Melanoma | 1 | 2014 | 772 | 0.020 |
Why?
| | ATP Binding Cassette Transporter 1 | 1 | 2006 | 11 | 0.020 |
Why?
| | Receptors, LDL | 1 | 2006 | 52 | 0.020 |
Why?
| | Gene Targeting | 1 | 2006 | 83 | 0.020 |
Why?
| | Syk Kinase | 1 | 2006 | 21 | 0.020 |
Why?
| | Fetal Distress | 1 | 2006 | 14 | 0.020 |
Why?
| | Random Allocation | 1 | 2006 | 367 | 0.010 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2006 | 109 | 0.010 |
Why?
| | Immunity | 1 | 2006 | 140 | 0.010 |
Why?
| | Hyperoxia | 1 | 2006 | 91 | 0.010 |
Why?
| | Nitrites | 1 | 2005 | 89 | 0.010 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 2006 | 106 | 0.010 |
Why?
| | RNA Interference | 1 | 2006 | 469 | 0.010 |
Why?
| | Tumor Suppressor Proteins | 1 | 2006 | 325 | 0.010 |
Why?
| | Caenorhabditis elegans Proteins | 1 | 2006 | 214 | 0.010 |
Why?
| | Drug Therapy, Combination | 1 | 2006 | 1040 | 0.010 |
Why?
| | Child | 2 | 2021 | 22310 | 0.010 |
Why?
| | Survival Analysis | 1 | 2006 | 1319 | 0.010 |
Why?
| | Genes, Dominant | 1 | 2003 | 97 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 2006 | 1261 | 0.010 |
Why?
| | Homeostasis | 1 | 2006 | 636 | 0.010 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2006 | 431 | 0.010 |
Why?
| | Chimera | 1 | 2002 | 61 | 0.010 |
Why?
| | Oxidation-Reduction | 1 | 2006 | 1086 | 0.010 |
Why?
| | Stroke Volume | 1 | 2005 | 587 | 0.010 |
Why?
| | Hypoxia | 1 | 2009 | 1164 | 0.010 |
Why?
| | Neovascularization, Physiologic | 1 | 2003 | 182 | 0.010 |
Why?
| | Neutrophil Infiltration | 1 | 2002 | 108 | 0.010 |
Why?
| | Double-Blind Method | 1 | 2006 | 1983 | 0.010 |
Why?
| | Respiratory Muscles | 1 | 2001 | 35 | 0.010 |
Why?
| | Interleukin-1 | 2 | 1996 | 968 | 0.010 |
Why?
| | Cell Count | 1 | 2002 | 326 | 0.010 |
Why?
| | Blood Gas Analysis | 1 | 2001 | 83 | 0.010 |
Why?
| | Enzyme Inhibitors | 1 | 2005 | 854 | 0.010 |
Why?
| | Cell Division | 1 | 2003 | 798 | 0.010 |
Why?
| | Chemokines | 1 | 2002 | 228 | 0.010 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2002 | 171 | 0.010 |
Why?
| | Stress, Mechanical | 1 | 2003 | 489 | 0.010 |
Why?
| | Bone Marrow Transplantation | 1 | 2002 | 294 | 0.010 |
Why?
| | Bleomycin | 1 | 2002 | 248 | 0.010 |
Why?
| | Hyaluronic Acid | 1 | 2002 | 226 | 0.010 |
Why?
| | Proteins | 1 | 2006 | 1010 | 0.010 |
Why?
| | Chemokine CCL3 | 1 | 1999 | 17 | 0.010 |
Why?
| | Chemokine CCL4 | 1 | 1999 | 22 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2003 | 1737 | 0.010 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 1999 | 83 | 0.010 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 1999 | 166 | 0.010 |
Why?
| | Shivering | 1 | 1996 | 5 | 0.010 |
Why?
| | Acute-Phase Reaction | 1 | 1996 | 39 | 0.010 |
Why?
| | Blood Cell Count | 1 | 1996 | 54 | 0.010 |
Why?
| | Toxemia | 1 | 1996 | 5 | 0.010 |
Why?
| | Lactoferrin | 1 | 1996 | 40 | 0.010 |
Why?
| | Sialoglycoproteins | 1 | 1996 | 159 | 0.010 |
Why?
| | Solubility | 1 | 1996 | 245 | 0.010 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 1996 | 255 | 0.010 |
Why?
| | Kinetics | 1 | 1999 | 1652 | 0.010 |
Why?
| | Calmodulin | 1 | 1994 | 71 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2006 | 6275 | 0.010 |
Why?
| | Cytosol | 1 | 1994 | 230 | 0.010 |
Why?
| | Phenotype | 1 | 2002 | 3166 | 0.010 |
Why?
| | Electrocardiography | 1 | 1996 | 618 | 0.010 |
Why?
| | Peptide Fragments | 1 | 1996 | 698 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 2006 | 2560 | 0.010 |
Why?
| | Cattle | 1 | 1994 | 998 | 0.010 |
Why?
| | Hemodynamics | 1 | 1996 | 1100 | 0.010 |
Why?
| | Interferon-gamma | 1 | 1994 | 792 | 0.010 |
Why?
| | Sulfonamides | 1 | 1994 | 520 | 0.010 |
Why?
| | Prospective Studies | 1 | 1996 | 7739 | 0.000 |
Why?
|
|
Vandivier's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|